Published 1 year ago

The Covid pandemic drives Pfizer's 2022 revenue to a record $100 billion

Summary by Ground News

The ongoing Covid-19 pandemic propelled pharmaceutical company Pfizer’s earnings to a record $100 billion last year, almost $57 billion of which was driven by its vaccine and antiviral pill Paxlovid, the company reported Tuesday.

0 Articles

All

Left

Center

Right

CNBC

The Covid pandemic drives Pfizer's 2022 revenue to a record $100 billion

Sales of Paxlovid surged to $18.9 billion in 2022 which was the first full-year that the antiviral pill was available.

1 year ago·United States

Read Full Article

The Hill

Pfizer anticipates billions less in revenue this year as vaccines commercialized

Pfizer executives said the company expects a significant drop in revenue in 2023 compared to 2022 as the U.S. government ends its purchase agreement for COVID-19 vaccines and treatments. During its 2022 fourth-quarter earnings call Tuesday, CEO Albert Bourla said he anticipates 2023 to be a “transition year” as advance government purchases end and the…

1 year ago·Washington, United States

Read Full Article

The Epoch Times

Pfizer Rakes in Billions on COVID-19 Vaccine Sales, Highest Revenue in Company’s History

Vaccine maker Pfizer has reported record revenues for 2022, with its COVID-19 products accounting for a large chunk of the sales even as the company is facing backlash for claiming to “mutate” viruses, and a growing number of doctors are turning away from boosters.

1 year ago·New York, United States

Read Full Article

Irish Examiner

Pfizer projects sharp fall in Covid vaccine and treatments this year

Pfizer has forecast a bigger-than-expected drop in sales of its Covid-19 vaccine and treatment for 2023, intensifying investor concerns over demand ...

1 year ago·Ireland

Read Full Article

El Pais

Pfizer, the first pharmaceutical company with a turnover of more than 100 billion a year

The Covid-19 vaccine boosts the revenues and profits of the New York giant

1 year ago·Spain

Read Full Article

MarketWatch

Moderna’s stock is down as Pfizer lowers revenue estimates for its COVID vaccine for 2023

Moderna Inc.’s shares were down 2.8% in trading on Tuesday. Pfizer Inc. which makes a competing COVID-19 vaccine to Moderna’s Spikevax, on Tuesday put out...

1 year ago·United States

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Ground News Article Assistant

Not enough coverage to generate an Article Assistant.

Coverage Details

Total News Sources0

Leaning Left5Leaning Right1Center3Last Updated1 year agoBias Distribution

56% Left

Bias Distribution

56% of the sources lean Left

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)

The Covid pandemic drives Pfizer's 2022 revenue to a record $100 billion

0 Articles

0 Articles

The Covid pandemic drives Pfizer's 2022 revenue to a record $100 billion

The Covid pandemic drives Pfizer's 2022 revenue to a record $100 billion

Pfizer anticipates billions less in revenue this year as vaccines commercialized

Pfizer anticipates billions less in revenue this year as vaccines commercialized

Pfizer Rakes in Billions on COVID-19 Vaccine Sales, Highest Revenue in Company’s History

Pfizer Rakes in Billions on COVID-19 Vaccine Sales, Highest Revenue in Company’s History

Pfizer projects sharp fall in Covid vaccine and treatments this year

Pfizer projects sharp fall in Covid vaccine and treatments this year

Pfizer, the first pharmaceutical company with a turnover of more than 100 billion a year

Pfizer, the first pharmaceutical company with a turnover of more than 100 billion a year

Moderna’s stock is down as Pfizer lowers revenue estimates for its COVID vaccine for 2023

Moderna’s stock is down as Pfizer lowers revenue estimates for its COVID vaccine for 2023

Coverage Details

Bias Distribution

Ownership

Similar News Topics

Similar News Topics